
MapLight Therapeutics, Inc.: updates and filings
Price
$5.94
November 20, 2026Market cap $315M
What Ploutos Investor adds for MapLight Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 17, 2026FilingFormEFFECT
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Material agreement enteredForm8-K
- Nov 16, 2026Shelf registration for future offeringsFormS-3
- Nov 16, 2026FilingFormPOS AM
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 16, 2026Results of operations, Regulation FD disclosureForm8-K
- Sep 23, 2026FilingFormEFFECT
- Sep 18, 2026Filing (amendment)FormS-1/A
- Sep 9, 2026FilingFormS-1
- Aug 20, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 18, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Material agreement entered, results of operations, unregistered sale of shares, Regulation FD disclosureForm8-K
- Aug 3, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 31, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 27, 2026Regulation FD disclosure, other material eventsForm8-K
- Jul 15, 2026Filing (amendment)Form144/A
- Jun 24, 2026Shareholder voteForm8-K
- Jun 22, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 18, 2026Officer or director changeForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operations, Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 17, 2026 | EFFECT | Filing | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | 8-K | Material agreement entered | Document |
| Nov 16, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 16, 2026 | POS AM | Filing | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 16, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Sep 23, 2026 | EFFECT | Filing | Document |
| Sep 18, 2026 | S-1/A | Filing (amendment) | Document |
| Sep 9, 2026 | S-1 | Filing | Document |
| Aug 20, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 18, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Material agreement entered, results of operations, unregistered sale of shares, Regulation FD disclosure | Document |
| Aug 3, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 31, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 27, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jul 15, 2026 | 144/A | Filing (amendment) | Document |
| Jun 24, 2026 | 8-K | Shareholder vote | Document |
| Jun 22, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 18, 2026 | 8-K | Officer or director change | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 8, 2019.
The full analysis
What do MapLight Therapeutics's filings show?
The filings are where every one of MapLight Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.